Recs – SNOMED CT Codes

Demonstration of identifying an extended set of SNOMEDCT codes to identify key concepts in each recommendation.
ID Recommendation All CUI codes
32470 A thorough history and physical examination should be obtained/ performed in patients presenting with Heart Failure to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the development or progression of Heart Failure. C0004927,C0018787,C0018801,C0019664,C0030705,C0031809,C0150618,C0205485,C0449258,C0521110,C0884358,C1527148,C4321457,C0012634,C0018799,C0031809,C0262926
32471 In patients with idiopathic dilated cardiomyopathy (DCM), a 3-generational family history should be obtained to aid in establishing the diagnosis of familial DCM. C0007193,C0011900,C0015576,C0019664,C0030705,C0241888,C0241889,C0700124,C0878544,C0011900,C0033141,C0241889,C0262926,C0878544
32472 Volume status and vital signs should be assessed at each patient encounter. This includes serial assessment of weight, as well as estimates of jugular venous pressure and the presence of peripheral edema or orthopnea. C0013604,C0030705,C0043100,C0085619,C0085649,C0205100,C0348013,C0428897,C0449438,C0449468,C0750572,C1516048,C1947978,C3146287,C0013604,C0085619,C0085649,C0311392,C0392148,C0428897,C0460139,C1261322
32474 Initial laboratory evaluation of patients presenting with Heart Failure should include a complete blood cell count, urinalysis, measurement of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, and thyroid-stimulating hormone, a fasting lipid profile, and liver function tests. C0005767,C0005771,C0005773,C0006675,C0007584,C0007634,C0010294,C0013832,C0015663,C0017725,C0018787,C0018801,C0019932,C0022877,C0023767,C0023779,C0023884,C0023901,C0024467,C0028158,C0030705,C0041942,C0042014,C0205197,C0205265,C0220825,C0229671,C0232741,C0242485,C0430044,C0587355,C0600137,C0750480,C0005767,C0005771,C0005773,C0005845,C0006675,C0007584,C0007634,C0009555,C0010294,C0013832,C0015663,C0017725,C0019932,C0023779,C0023884,C0023901,C0024467,C0028158,C0040132,C0040135,C0040160,C0041942,C0042014,C0201976,C0229671,C0430044,C0587355,C0600137,C1261322,C1269647,C1278929,C1291218
32475 Serial monitoring, when indicated, should include serum electrolyte levels and renal function. C0013832,C0229671,C0232804,C1444656,C0013832,C0181904,C0229671,C1287347,C2946261
32476 A 12-lead electrocardiogram should be performed initially on all patients presenting with Heart Failure C0013798,C0018787,C0018801,C0023175,C0030705,C0205265,C0884358,C0013798,C0023175,C1623258
32477 Screening for hemochromatosis or HIV is reasonable in selected patients who present with Heart Failure. C0018787,C0018801,C0018995,C0030705,C0150312,C1710032,C0018995,C0220908
32478 Diagnostic tests for rheumatological diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with Heart Failure in whom there is a clinical suspicion of these diseases. C0002726,C0012634,C0018787,C0018801,C0030705,C0031511,C0205210,C0242114,C0348026,C0002726,C0012634,C0031511
32479 For patients at risk of developing Heart Failure, natriuretic peptide biomarker–based screening followed by team-based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset Heart Failure. C0018787,C0018801,C0030705,C0030956,C0035647,C0205091,C0332283,C0388060,C0597421,C0749225,C1277187,C1522565,C1527148,C1611835,C1710032,C3827682,C3887460,C3887504,C0030956,C0220908,C1273070,C1277187
32480 In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of Heart Failure. C0011900,C0013404,C0018787,C0018801,C0030705,C0030956,C0242485,C0388060,C0597421,C2828389,C3827682,C4518809,C0011900,C0013404,C0030956
32481 Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic Heart Failure. C0012634,C0018787,C0018801,C0205191,C0242485,C0264716,C3827682,C0012634,C0033325
32482 Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated Heart Failure. C0018787,C0018801,C0019994,C0030956,C0041199,C0184666,C0205434,C0242485,C0388060,C0443211,C0457453,C0597421,C1442488,C3827682,C0030956,C0033325,C0041199,C0184666,C2946261
32483 During a Heart Failure hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis. C0018787,C0018801,C0019993,C0030956,C0347984,C0388060,C0443211,C0597421,C2946261,C3827682,C0030956,C0033325,C2946261
32484 In patients with chronic Heart Failure, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification. C0016059,C0018787,C0018801,C0030705,C0035647,C0205191,C0205394,C0242485,C0264716,C0442796,C0750591,C1514983,C1522564,C0016059,C0449210,C3263722,C3263723
32485 Patients with suspected or new-onset Heart Failure, or those presenting with acute decompensated Heart Failure, should undergo a chest x-ray to assess heart size and pulmonary congestion and to detect alternative cardiac, pulmonary, and other diseases that may cause or contribute to the patient’s symptoms. C0012634,C0018787,C0018801,C0030705,C0205178,C0205394,C0205434,C0242073,C0456389,C0700148,C0817096,C1457887,C1523987,C0012634,C0018787,C0018799,C0039985,C0242073,C0449210,C0700148,C0817096,C1281570,C1306645,C1457887,C1962945
32486 A 2-dimensional echocardiogram with Doppler should be performed during initial evaluation of patients presenting with Heart Failure to assess ventricular function, size, wall thickness, wall motion, and valve function. C0018787,C0018801,C0026597,C0030705,C0205265,C0220825,C0347984,C0456389,C0884358,C1522565,C1705052,C0013516,C0554756,C1261322
32487 Repeat measurement of EF and measurement of the severity of structural remodeling are useful to provide information in patients with Heart Failure who have had a significant change in clinical status; who have experienced or recovered from a clinical event; or who have received treatment, including GDMT, that might have had a significant effect on cardiac function; or who may be candidates for device therapy. C0018787,C0018801,C0030705,C0205210,C0205341,C0232164,C0242485,C0441471,C0449438,C0449440,C0699733,C0750502,C1280500,C1514756,C1533716,C3827682,C0087111
32488 Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients presenting with de novo Heart Failure, who have known CAD and no angina, unless the patient is not eligible for revascularization of any kind. C0018787,C0018801,C0022116,C0030705,C0151744,C0205309,C1522564,C1548635,C2986496,C0002962,C0011923,C0022116,C0151744,C0581603
32489 Viability assessment is reasonable in select situations when planning revascularization in Heart Failure patients with CAD. C0018787,C0018801,C0030705,C0581603,C1261322
32490 Radionuclide ventriculography or magnetic resonance imaging can be useful to assess LVEF and volume when echocardiography is inadequate. C0013516,C0024485,C0034610,C0449468,C3827682,C0011923,C0013516,C0024485,C0034610,C0231881
32491 Magnetic resonance imaging is reasonable when assessing myocardial infiltrative processes or scar burden. C0024485,C1522564,C2828008,C0011923,C0024485,C0231881,C2004491
32492 Routine repeat measurement of LV function assessment in the absence of clinical status change or treatment interventions should NOT be performed. C0205210,C0205341,C0205547,C0242485,C0449438,C0449440,C0884358,C1261322,C1273869,C1689985
32493 Invasive hemodynamic monitoring with a pulmonary artery catheter should be performed to guide therapy in patients who have respiratory distress or clinical evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from clinical assessment. C0019010,C0030705,C0205210,C0205281,C0221099,C0231303,C0476273,C0521346,C0884358,C1979886,C3887511,C4082936,C0003842,C0031001,C0034052,C0085590,C0087111,C0150264,C0161959,C0179790,C0181904,C0302614,C0460139,C0476273,C0729936,C1261322,C1269026
32494 Invasive hemodynamic monitoring can be useful for carefully selected patients with acute Heart Failure who have persistent symptoms despite empiric adjustment of standard therapies, and: • Whose fluid status, perfusion, or systemic or pulmonary vascular resistance is uncertain; • Whose systolic pressure remains low, or is associated with symptoms, despite initial therapy; • Whose renal function is worsening with therapy; • Who require parenteral vasoactive agents; or • Who may need consideration for mechanical circulatory support (MCS) or transplantation. C0018787,C0018801,C0019010,C0027552,C0030705,C0040732,C0042380,C0205178,C0205265,C0205281,C0205322,C0205373,C0232804,C0264714,C0449438,C0456261,C0518609,C0871470,C1457887,C1801960,C1880496,C1980011,C3827682,C4082936,C4281815,C0031001,C0040732,C0087111,C0150264,C0161959,C0181904,C0183683,C0344211,C0450442,C0460139,C1457887
32495 When ischemia may be contributing to Heart Failure, coronary arteriography is reasonable for patients eligible for revascularization. C0003844,C0018787,C0018801,C0022116,C0030705,C1522318,C1548635,C0003844,C0022116,C0085532,C0581603
32496 Endomyocardial biopsy can be useful in patients presenting with Heart Failure when a specific diagnosis is suspected that would influence therapy. C0005558,C0011900,C0018787,C0018801,C0030705,C3827682,C4054723,C0005558,C0011900,C0087111,C0189785
32497 Routine use of invasive hemodynamic monitoring is NOT recommended in normotensive patients with acute decompensated Heart Failure and congestion with symptomatic response to diuretics and vasodilators. C0012798,C0018787,C0018801,C0019010,C0030705,C0205178,C0205281,C0205434,C0205547,C0231220,C0700148,C3846195,C4082936,C0012798,C0042402,C0150264,C0161959,C0181904,C0522563,C0700148,C2712122
32498 Endomyocardial biopsy should NOT be performed in the routine evaluation of patients with Heart Failure. C0005558,C0018787,C0018801,C0030705,C0205547,C0220825,C0884358,C0005558,C0189785,C1261322
32500 Other conditions that may lead to or contribute to Heart Failure, such as obesity, diabetes mellitus, tobacco use, and known cardiotoxic agents, should be controlled or avoided. C0011847,C0011849,C0018787,C0018801,C0023175,C0028754,C0040329,C0205309,C0205394,C0011849,C0028754,C0040329,C0449210,C0450442
32501 In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, angiotensin-converting enzyme (ACE) inhibitors should be used to prevent symptomatic Heart Failure and reduce mortality. In patients intolerant of ACE inhibitors, angiotensin-receptor blockers are appropriate unless contraindicated. C0014442,C0018787,C0018801,C0019664,C0030705,C0039082,C0205157,C0205178,C0231200,C0231220,C0243077,C0332185,C0392756,C0948089,C1444657,C1522318,C1548787,C0003015,C0003018,C0014442,C0022709,C0034787,C0039082,C0262926,C0597357,C0948089
32503 In all patients with a recent or remote history of MI or acute coronary syndrome and reduced EF, evidence-based beta blockers should be used to reduce mortality. C0019664,C0030705,C0039082,C0205157,C0205178,C0332185,C0392756,C0948089,C1522318,C0039082,C0262926,C0948089
32504 In all patients with a recent or remote history of MI or acute coronary syndrome, statins should be used to prevent symptomatic Heart Failure and cardiovascular events. C0018787,C0018801,C0019664,C0030705,C0039082,C0205157,C0205178,C0231220,C0332185,C0441471,C0948089,C1522318,C3887460,C0039082,C0262926,C0360714,C0948089,C1320716
32505 In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic Heart Failure. C0005767,C0005823,C0018787,C0018801,C0019664,C0020564,C0030705,C0162791,C0205210,C0231220,C0005767,C0020538,C0020564,C0149721,C0262926,C0460139,C1272641,C1689985
32506 ACE inhibitors should be used in all patients with a reduced EF to prevent symptomatic Heart Failure, even if they do not have a history of MI. C0018787,C0018801,C0019664,C0030705,C0231220,C0243077,C0392756,C0003015,C0262926
32507 Beta blockers should be used in all patients with a reduced EF to prevent symptomatic Heart Failure, even if they do not have a history of MI. C0018787,C0018801,C0019664,C0030705,C0231220,C0392756,C0262926
32508 To prevent sudden death, placement of an implantable cardioverterdefibrillator (ICD) is reasonable in patients with asymptomatic ischemic cardiomyopathy who are ?40 days post-MI, have an LVEF of ?30%, are on appropriate medical therapy, and have a reasonable expectation of survival with a good functional status for >1 year. C0011071,C0030705,C0205170,C0205245,C0205476,C0231221,C0349782,C0418981,C0439234,C0449438,C0475224,C0679138,C0878544,C1524072,C1548787,C0011071,C0087111,C0231221,C0349782,C0418981,C0441587,C0878544,C1306577,C1533810
32509 Nondihydropyridine calcium channel blockers with negative inotropic effects may be harmful in asymptomatic patients with low LVEF and no symptoms of Heart Failure after MI. C0006675,C0018787,C0018801,C0030705,C0205160,C0231221,C0439799,C1280500,C1457887,C1704420,C0006675,C0006684,C0231221,C1457887